It’s Wednesday at the 2017 JP Morgan Healthcare Conference and the last full day of the meeting.
It’s also our last day for a rolling blog; we hope you’ve enjoyed our coverage and commentary this year.
If you want to catch up on what we’ve written about, do check out our posts form Day 1 (Link) and Day 2 of JPM17 (Link).
Yesterday also included some thoughts on the latest Merck pembrolizumab filing announcement in 1L NSCLC, which has certainly had a dramatic impact on the market, even for big pharma (MRK +$4.9B, BMY -$3.3B).
Companies we’ve covered so far include: Celgene, Incyte, Seattle Genetics, Clovis, Puma, BMS, Five Prime, Nektar, Juno and others.
Subscribers can login to read more
It was only five years ago that the number of abstracts on CAR T cell therapies at the American Society of Hematology (ASH) ran to a dozen or less. Fast forward to 2016 and we now have tens of them, almost too many to count, let along review quickly and easily.
A scene from ASH 2015…
To give you an idea of the staggering speed of progress, in 2010 it took me less than half an hour to search and read all the CAR T cell abstracts, now it takes nearly a whole day to peruse and review them carefully.
We can’t resist a challenge…
As usual, we will write in more depth from the meeting as the data emerges in real time since many of the abstracts are often placeholders with updated information provided at the conference itself.
For now, here we provide an in-depth preview of the CAR T cell landscape in terms of the players, the products, new scientific research, biomarkers, emerging trends and more in a handy What to Watch For (W2W4) guide on key areas to expect at ASH to enable better enjoyment and awareness as the data rolls out next month.
Subscribers can log-in to learn more insights and which highlights matter…